IMMvention Therapeutix
Biotechnology
IMMvention Therapeutix is a venture-funded company that is discovering and developing a first-in-class BACH1 inhibitor as oral therapy for patients with sickle cell disease. IMMvention is working with Novo Nordisk to further develop this technology, addressing unmet needs in sickle cell disease and beyond.
Additional Details
- Company Size:
- 1-9 Employees